119 related articles for article (PubMed ID: 24619665)
21. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.
Aarntzen EH; Schreibelt G; Bol K; Lesterhuis WJ; Croockewit AJ; de Wilt JH; van Rossum MM; Blokx WA; Jacobs JF; Duiveman-de Boer T; Schuurhuis DH; Mus R; Thielemans K; de Vries IJ; Figdor CG; Punt CJ; Adema GJ
Clin Cancer Res; 2012 Oct; 18(19):5460-70. PubMed ID: 22896657
[TBL] [Abstract][Full Text] [Related]
22. Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells.
Schuurhuis DH; Lesterhuis WJ; Kramer M; Looman MG; van Hout-Kuijer M; Schreibelt G; Boullart AC; Aarntzen EH; Benitez-Ribas D; Figdor CG; Punt CJ; de Vries IJ; Adema GJ
Cancer Immunol Immunother; 2009 Jul; 58(7):1109-15. PubMed ID: 19018531
[TBL] [Abstract][Full Text] [Related]
23. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients.
Wilgenhof S; Van Nuffel AMT; Benteyn D; Corthals J; Aerts C; Heirman C; Van Riet I; Bonehill A; Thielemans K; Neyns B
Ann Oncol; 2013 Oct; 24(10):2686-2693. PubMed ID: 23904461
[TBL] [Abstract][Full Text] [Related]
24. Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols.
Dullaers M; Breckpot K; Van Meirvenne S; Bonehill A; Tuyaerts S; Michiels A; Straetman L; Heirman C; De Greef C; Van Der Bruggen P; Thielemans K
Mol Ther; 2004 Oct; 10(4):768-79. PubMed ID: 15451461
[TBL] [Abstract][Full Text] [Related]
25. Antigen-specific mRNA transfection of autologous dendritic cells.
Benencia F
Methods Mol Biol; 2014; 1139():77-86. PubMed ID: 24619672
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
[TBL] [Abstract][Full Text] [Related]
27. Clinical scale electroloading of mature dendritic cells with melanoma whole tumor cell lysate is superior to conventional lysate co-incubation in triggering robust in vitro expansion of functional antigen-specific CTL.
Wolfraim LA; Takahara M; Viley AM; Shivakumar R; Nieda M; Maekawa R; Liu LN; Peshwa MV
Int Immunopharmacol; 2013 Mar; 15(3):488-97. PubMed ID: 23474736
[TBL] [Abstract][Full Text] [Related]
28. Effective clinical-scale production of dendritic cell vaccines by monocyte elutriation directly in medium, subsequent culture in bags and final antigen loading using peptides or RNA transfection.
Erdmann M; Dörrie J; Schaft N; Strasser E; Hendelmeier M; Kämpgen E; Schuler G; Schuler-Thurner B
J Immunother; 2007 Sep; 30(6):663-74. PubMed ID: 17667530
[TBL] [Abstract][Full Text] [Related]
29. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
[TBL] [Abstract][Full Text] [Related]
30. Induction of Influenza Matrix Protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells.
Tuyaerts S; Michiels A; Corthals J; Bonehill A; Heirman C; de Greef C; Noppe SM; Thielemans K
Cancer Gene Ther; 2003 Sep; 10(9):696-706. PubMed ID: 12944989
[TBL] [Abstract][Full Text] [Related]
31. Messenger RNA electroporation of human monocytes, followed by rapid in vitro differentiation, leads to highly stimulatory antigen-loaded mature dendritic cells.
Ponsaerts P; Van den Bosch G; Cools N; Van Driessche A; Nijs G; Lenjou M; Lardon F; Van Broeckhoven C; Van Bockstaele DR; Berneman ZN; Van Tendeloo VF
J Immunol; 2002 Aug; 169(4):1669-75. PubMed ID: 12165485
[TBL] [Abstract][Full Text] [Related]
32. Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines.
Michiels A; Tuyaerts S; Bonehill A; Corthals J; Breckpot K; Heirman C; Van Meirvenne S; Dullaers M; Allard S; Brasseur F; van der Bruggen P; Thielemans K
Gene Ther; 2005 May; 12(9):772-82. PubMed ID: 15750615
[TBL] [Abstract][Full Text] [Related]
33. CD40 ligand is essential for generation of specific cytotoxic T cell responses in RNA-pulsed dendritic cell immunotherapy.
Onaitis MW; Kalady MF; Emani S; Abdel-Wahab Z; Tyler DS; Pruitt SK
Surgery; 2003 Aug; 134(2):300-5. PubMed ID: 12947333
[TBL] [Abstract][Full Text] [Related]
34. Immune Monitoring Using mRNA-Transfected Dendritic Cells.
Borch TH; Svane IM; Met Ö
Methods Mol Biol; 2016; 1428():245-59. PubMed ID: 27236804
[TBL] [Abstract][Full Text] [Related]
35. RNA loading of leukemic antigens into cord blood-derived dendritic cells for immunotherapy.
Hsu AK; Kerr BM; Jones KL; Lock RB; Hart DN; Rice AM
Biol Blood Marrow Transplant; 2006 Aug; 12(8):855-67. PubMed ID: 16864056
[TBL] [Abstract][Full Text] [Related]
36. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70.
Zobywalski A; Javorovic M; Frankenberger B; Pohla H; Kremmer E; Bigalke I; Schendel DJ
J Transl Med; 2007 Apr; 5():18. PubMed ID: 17430585
[TBL] [Abstract][Full Text] [Related]
37. Cytokines in the generation and maturation of dendritic cells: recent advances.
Zou GM; Tam YK
Eur Cytokine Netw; 2002; 13(2):186-99. PubMed ID: 12101074
[TBL] [Abstract][Full Text] [Related]
38. Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ T cell tolerance and permits effective immunity.
Keller AM; Schildknecht A; Xiao Y; van den Broek M; Borst J
Immunity; 2008 Dec; 29(6):934-46. PubMed ID: 19062317
[TBL] [Abstract][Full Text] [Related]
39. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial.
Van Driessche A; Van de Velde AL; Nijs G; Braeckman T; Stein B; De Vries JM; Berneman ZN; Van Tendeloo VF
Cytotherapy; 2009; 11(5):653-68. PubMed ID: 19530029
[TBL] [Abstract][Full Text] [Related]
40. Efficient genetic modification of murine dendritic cells by electroporation with mRNA.
Van Meirvenne S; Straetman L; Heirman C; Dullaers M; De Greef C; Van Tendeloo V; Thielemans K
Cancer Gene Ther; 2002 Sep; 9(9):787-97. PubMed ID: 12189529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]